CLINICAL TRIALS PROFILE FOR PYRIDOSTIGMINE BROMIDE
✉ Email this page to a colleague
All Clinical Trials for PYRIDOSTIGMINE BROMIDE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00223691 ↗ | Treatment of Orthostatic Hypotension in Autonomic Failure | Completed | Vanderbilt University | Phase 1 | 2002-03-01 | The autonomic nervous system serves multiple regulatory functions in the body, including the regulation of blood pressure and heart rate, gut motility, sweating and sexual function. There are several diseases characterized by abnormal function of the autonomic nervous system. Medications can also alter autonomic function. Impairment of the autonomic nervous system by diseases or drugs may lead to several symptoms, including blood pressure problems (e.g., high blood pressure lying down and low blood pressure on standing), sweating abnormalities, constipation or diarrhea and sexual dysfunction. Because treatment options for these patients are limited. We propose to study patients autonomic failure and low blood pressure upon standing and determine the cause of their disease by history and examination and their response to autonomic testing which have already been standardized in our laboratory. Based on their possible cause, we will tests different medications that may alleviate their symptoms. |
| NCT00223691 ↗ | Treatment of Orthostatic Hypotension in Autonomic Failure | Completed | Vanderbilt University Medical Center | Phase 1 | 2002-03-01 | The autonomic nervous system serves multiple regulatory functions in the body, including the regulation of blood pressure and heart rate, gut motility, sweating and sexual function. There are several diseases characterized by abnormal function of the autonomic nervous system. Medications can also alter autonomic function. Impairment of the autonomic nervous system by diseases or drugs may lead to several symptoms, including blood pressure problems (e.g., high blood pressure lying down and low blood pressure on standing), sweating abnormalities, constipation or diarrhea and sexual dysfunction. Because treatment options for these patients are limited. We propose to study patients autonomic failure and low blood pressure upon standing and determine the cause of their disease by history and examination and their response to autonomic testing which have already been standardized in our laboratory. Based on their possible cause, we will tests different medications that may alleviate their symptoms. |
| NCT00953914 ↗ | Pyridostigmine and Its Effects on Autonomic Modulation in Diabetic Patients | Completed | Hospital de Clinicas de Porto Alegre | N/A | 2005-03-01 | The purpose of the study is to determine if pyridostigmine bromide improves heart rate variability of type 2 diabetes mellitus subjects with cardiovascular autonomic neuropathy. |
| NCT01370512 ↗ | Droxidopa / Pyridostigmine in Orthostatic Hypotension | Completed | National Institute of Neurological Disorders and Stroke (NINDS) | Phase 2 | 2011-11-01 | The hypothesis is that pyridostigmine will improve the safety factor of ganglionic neural transmission, while Droxidopa will replete the postganglionic neuron of norepinephrine (NE). This combination should result in enhanced orthostatic release of NE. The investigators have already demonstrated that pyridostigmine does not raise supine blood pressure. |
| NCT01370512 ↗ | Droxidopa / Pyridostigmine in Orthostatic Hypotension | Completed | Mayo Clinic | Phase 2 | 2011-11-01 | The hypothesis is that pyridostigmine will improve the safety factor of ganglionic neural transmission, while Droxidopa will replete the postganglionic neuron of norepinephrine (NE). This combination should result in enhanced orthostatic release of NE. The investigators have already demonstrated that pyridostigmine does not raise supine blood pressure. |
| NCT01415921 ↗ | Safety Study of Pyridostigmine in Heart Failure | Completed | Nathan Kline Institute for Psychiatric Research | Phase 2 | 2011-10-01 | Heart failure, a common heart disease affecting nearly 6 million Americans, is associated with high rates of hospitalization and death. Abnormalities in the autonomic nervous system are thought to play an important role in the progression of heart failure. This proposal aims to determine whether novel application of pyridostigmine, a drug currently approved by the FDA only for the treatment of neuromuscular disease, can improve autonomic nervous system function in heart failure patients. |
| NCT01415921 ↗ | Safety Study of Pyridostigmine in Heart Failure | Completed | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 | 2011-10-01 | Heart failure, a common heart disease affecting nearly 6 million Americans, is associated with high rates of hospitalization and death. Abnormalities in the autonomic nervous system are thought to play an important role in the progression of heart failure. This proposal aims to determine whether novel application of pyridostigmine, a drug currently approved by the FDA only for the treatment of neuromuscular disease, can improve autonomic nervous system function in heart failure patients. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for PYRIDOSTIGMINE BROMIDE
Condition Name
Clinical Trial Locations for PYRIDOSTIGMINE BROMIDE
Trials by Country
Clinical Trial Progress for PYRIDOSTIGMINE BROMIDE
Clinical Trial Phase
Clinical Trial Sponsors for PYRIDOSTIGMINE BROMIDE
Sponsor Name
| Sponsor Name for PYRIDOSTIGMINE BROMIDE | |
| Sponsor | Trials |
| Vanderbilt University Medical Center | 2 |
| Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | 2 |
| James J. Peters Veterans Affairs Medical Center | 2 |
| [disabled in preview] | 4 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
